who's who

3 Houston innovators to know this week

This week's innovators to know include Richard Seline of ResilientH20, Adrianne Stone of Capital Factory, and Ethan Saadia of Wayt. Courtesy photos

Editor's note: All three of this week's Houston innovators to know started something new amid a global pandemic — a new job at a Texas-wide accelerator, a new app to help shops and businesses safely serve customers, and a new resilience-focused hub that launched just in time for hurricane season.

Richard Seline, managing director of ResilientH20

Richard Seline of ResilientH2O Partners explains how he's helping foster new hurricane and flood prevention technologies in the Bayou City. Photo courtesy of ResilientH20

Following Hurricane Harvey, Richard Seline saw several emerging startups focusing on flood tech. Meanwhile, he saw insurance companies very interested in finding new technologies in the same space. But, these two entities were not talking.

"It's two different languages," Seline says on the Houston Innovators Podcast. "There's a whole language and a whole mindset within the insurance industry that is not real well known."

Seline, managing director of ResilientH20, along with the Insurance Information Institute and The Cannon, has launched the Gulf Coast & Southwest Resilience Innovation Hub to foster this type of technology and bring insuratech startups and the big insurance players to the table. Stream the podcast and read more.

Adrianne Stone, venture associate for Capital Factory

Adrianne Stone has joined Capital Factory's Houston operations as the company prioritizes digital startup interaction. Photo courtesy of Capital Factory

After spending a year and a half in Silicon Valley on the products team for 23andme, Adrianne Stone is back in Houston, filling the venture associate role for Capital Factory. Stone got her Ph.D from Baylor College of Medicine and replaces Brittany Barreto, another BCM Ph.D who left the position to pursue a new venture.

"The mindset in Silicon Valley is different from how it is here in Texas — in good ways and bad ways. It was interesting to be exposed to a very potent startup vibe," Stone tells InnovationMap. "I'm looking forward to being able to meet all the cool companies, founders, and investors we have here in the Houston area." Read more.

Ethan Saadia, app developer and creator of Wayt

Ethan Saadia, a 17-year-old high school student, created an app to improve the user experience of shopping during a pandemic. Photo courtesy of Wayt

Like most of the world, Ethan Saadia has seen small, local businesses suffer from the social distancing mandates amid the COVID-19 outbreak. Saadia, a rising high school senior, wanted to do something to help.

He created Wayt, a smartphone app that provides businesses and their customers with a platform to communicate making curbside pickup, booking appointments, and even join a virtual line. Ultimately, Wayt has a great opportunity to help businesses — even outside of a pandemic

"From my perspective and experiences from my friends and family," says Saadia, "curbside pickup and virtual lines are definitely here to stay because even before the pandemic, popular places used to have long lines and that presented many new challenges. The pandemic is just accelerating technological change that will make our lives easier." Read more.

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News